The U.S. Food and Drug Administration has allowed Google-backed company 23andMe to begin marketing a home genetic test for Bloom Syndrome — an inherited condition characterized by shortness of height and increased risk of cancer.
The FDA also announced that it intends to exempt similar genetic testing devices from its premarket review protocol.
Screening tests are largely used by prospective parents who are concerned that their future children may inherent harmful genetic disorders.
“Today’s authorization … along with FDA’s intent to exempt these devices from FDA premarket review, supports innovation and will ultimately benefit consumers” stated spokesman Alberto Gutierrez.
More Must-Reads From TIME
- Taylor Swift Is TIME's 2023 Person of the Year
- Meet the Nation Builders
- Why Cell Phone Reception Is Getting Worse
- Column: It's Time to Scrap the Abraham Accords
- Israeli Family Celebrates Release of Hostage Grandmother
- In a New Movie, Beyoncé Finds Freedom
- The Top 100 Photos of 2023
- Want Weekly Recs on What to Watch, Read, and More? Sign Up for Worth Your Time
